Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Mindbio Therapeutics Corp. ( (TSE:MBIO) ) is now available.
MindBio Therapeutics Corp., a biotechnology company specializing in AI-based voice analytics for intoxication detection, has developed Intox Collect, a new software platform that scales the collection and analysis of voice and facial recognition data. The system enhances testing for stimulants and depressants affecting the central nervous system, leveraging an AI model trained on over 50 million data points to improve accuracy in predicting drug and alcohol impairment.
The company positions the technology as a potential game changer for regulated industries such as mining, aviation and construction, where high-volume, non-invasive and cost-efficient testing is critical. MindBio also corrected prior disclosure on its recent private placement, detailing updated finder’s fees and warrants, while the expanded capital base supports ongoing development of its Edge AI hardware-software kiosks slated for testing later in Q2 2026.
More about Mindbio Therapeutics Corp.
MindBio Therapeutics Corp. is a biotechnology company focused on commercialising AI-driven prediction technologies for drug and alcohol intoxication detection using voice analysis. The company is building an enterprise platform with Edge-AI kiosks that integrate bespoke hardware and software for non-invasive screening across mining, aviation, construction and law enforcement environments.
Average Trading Volume: 12,370
Technical Sentiment Signal: Sell
Current Market Cap: C$5.27M
Learn more about MBIO stock on TipRanks’ Stock Analysis page.